# Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

> **NCT02979561** · PHASE4 · UNKNOWN · sponsor: **Meshalkin Research Institute of Pathology of Circulation** · enrollment: 200 (estimated)

## Conditions studied

- Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy

## Interventions

- **DRUG:** Dabigatran Etexilate
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02979561
- **Lead sponsor:** Meshalkin Research Institute of Pathology of Circulation
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2016-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979561, "Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02979561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*